Throat lozenges could be contributing to antimicrobial resistance
pharmafile | April 12, 2019 | News story | Medical Communications | AMR, Antibiotics, OTC, WHO, antimicrobial, health
Over the counter (OTC) throat lozenges could be contributing to antimicrobial resistance (AMR) according to research presented at this year’s European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Amsterdam.
The inappropriate use of OTC sore throat medications that contain antibiotics could thus be preventing hindering the WHO’s plans to tackle AMR in order to “ensure, for as long as possible, continuity of successful treatment and prevention of infectious diseases with effective and safe medicines.”
A number of medications used to treat sore throats contain topical antibiotics. Many of these products are available in various European countries including the UK.
However the research commissioned by Reckitt Benckiser Healthcare Ltd, found the concentrations of these topical antibiotics were not high enough to kill some bacteria. This could contribute to AMR.
The researchers exposed the bacteria Staphylococcus aureus, Acinetobacter baumannii, Streptococcus pyogenes and Haemophilus influenza to decreasing concentrations of the antibiotics neomycin, bacitracin and tyrothricin, at a temperature of 37 °C.
While some of the antibiotics worked against some of the bacteria at the concentrations used in cough sweets, S. pyogenes showed growth in very week concentrations of neomycin while S. aureus showed growth in higher concentrations after 144 hours. The S. aureus bacteria were also discovered to have developed cross resistance to gentamicin, fusidic acid, and ciprofloxacin.
“We were concerned to find that some of the OTC antibiotics used in sore throat preparations were not sufficiently concentrated to prevent growth of common human pathogens and are enabling these pathogens to develop resistance. In addition, exposure to both standard and diluted concentrations of bacitracin was associated with clinical cross-resistance to other antibiotics,” Adrian Shephard of Reckitt Benckiser Healthcare Ltd, said.
“Our work raises doubt about the continued OTC availability of these antibiotics for the treatment of sore throats, especially considering the primarily viral nature of the condition.”
“This was an interesting study that showed once again the potential of bacteria to adapt to chemotherapeutic antibiotics highlighting the need for a prudent and perhaps controlled use of antibiotics in practice,” co-author Jean-Yves Maillard, Professor of Pharmaceutical Microbiology at Cardiff University, said.
Louis Goss
Related Content
WHO recommends new vaccine for prevention of malaria in children
The World Health Organization (WHO) has announced that it has recommended a new vaccine, R21/Matrix-M, …
BactiVac funds development of bacterial vaccines to prevent infections against antimicrobial resistance
The University of Birmingham hosted Bacterial Vaccines Network has been awarded £1.4m in funding from …
FDA approves a second OTC naloxone nasal spray
The US Food and Drug Administration (FDA) has announced that it has approved RiVive, 3mg …
